139 related articles for article (PubMed ID: 21221201)
21. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
[TBL] [Abstract][Full Text] [Related]
22. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
23. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
[TBL] [Abstract][Full Text] [Related]
24. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
[TBL] [Abstract][Full Text] [Related]
25. Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer.
Cramer SD; Sun J; Zheng SL; Xu J; Peehl DM
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2451-7. PubMed ID: 18768516
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
[TBL] [Abstract][Full Text] [Related]
27. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia.
Lee SH; Park TJ; Bae MH; Choi SH; Cho YS; Joo KJ; Kwon CH; Park HJ
Korean J Urol; 2013 Nov; 54(11):750-5. PubMed ID: 24255756
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide synthase 2 gene polymorphisms are associated with prostatic volume in Korean men with benign prostatic hyperplasia.
Yoo KH; Kim SK; Chung JH; Chang SG
Asian J Androl; 2010 Sep; 12(5):690-6. PubMed ID: 20562898
[TBL] [Abstract][Full Text] [Related]
29. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population.
Soni A; Bansal A; Mishra AK; Batra J; Singh LC; Chakraborty A; Yadav DS; Mohanty NK; Saxena S
Genet Test Mol Biomarkers; 2012 Aug; 16(8):835-40. PubMed ID: 22731640
[TBL] [Abstract][Full Text] [Related]
30. Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostate specific antigen levels in patients with benign prostatic hyperplasia?
Di Silverio F; Sciarra A; Monti S; Casale P; Seccareccia F
J Urol; 1999 Jan; 161(1):128-32. PubMed ID: 10037384
[TBL] [Abstract][Full Text] [Related]
31. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
[TBL] [Abstract][Full Text] [Related]
32. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
33. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
36. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
37. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
38. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
39. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
